2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2008090927v1 20/7/1527    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Gattone, V. H. Articles by Moe, S. M. PubMed PubMed Citation Articles by Gattone, V. H., II Articles by Moe, S. M. Related Collections Related Articles

Calcimimetic Inhibits Late-Stage Cyst Growth in ADPKD

Vincent H. Gattone, II^*, Neal X. Chen, Rachel M. Sinders^*, Mark F. Seifert^*, Danxia Duan, David Martin, Charles Henley and Sharon M. Moe^,

^* Departments of Anatomy and Cell Biology, and Medicine, Indiana University School of Medicine, Indianapolis, Indiana; Department of Metabolic Disorders, Amgen, Inc., Thousand Oaks, California; and Roudebush VA Medical Center, Indianapolis, Indiana

Correspondence: Dr. Vincent H. Gattone II, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, Indiana 46202. Phone: 317-274-2505; Fax 317-278-2040; E-mail: vgattone{at}iupui.edu

Received for publication September 3, 2008. Accepted for publication March 2, 2009.

In polycystic kidney disease (PKD), genetic mutations in polycystin 1 and 2 lead to defective intracellular trafficking of calcium, thereby decreasing intracellular calcium and altering cAMP signaling to favor proliferation. We hypothesized that calcimimetics, allosteric modulators of the calcium-sensing receptor, would reduce cyst growth by increasing intracellular calcium. We randomly assigned 20-wk-old male rats with a form of autosomal dominant PKD (heterozygote Cy/+) to one of four groups for 14 to 18 wk of treatment: (group 1) no treatment; (group 2) calcimimetic R-568 formulated in the diet; (group 3) R-568 plus calcium-supplemented drinking water (R-568 plus Ca); or (group 4) Ca-supplemented drinking water with a normal diet (Ca). Severity of PKD did not progress in any of the three treatment groups between 34 and 38 wk. Compared with no treatment, cyst growth was unaffected at 34 wk by all treatments, but cyst volume and fibrosis were lower at 38 wk, with both R-568-treated groups demonstrating a greater reduction than calcium alone. Between 34 and 38 wk, the total kidney weight increased by 78% in the control group (P < 0.001) and by 19% in the Ca group (P < 0.01), but did not increase in the R-568 or R-568 plus Ca groups, suggesting inhibition of disease progression despite equivalent suppression of parathyroid hormone. In summary, treatment of hyperparathyroidism halts late-stage progression of rodent cystic kidney disease. The benefit of R-568 alone suggests calcium-sensing receptor modulation may have additional inhibitory effects on late-stage cyst growth resulting from a direct modulation of intracellular calcium.

Related Articles

This Month's Highlights
J. Am. Soc. Nephrol. 2009 20: A13. [Full Text] [PDF]

This article has been cited by other articles:

				V. E. Torres Type II Calcimimetics and Polycystic Kidney Disease: Unanswered Questions J. Am. Soc. Nephrol., July 1, 2009; 20(7): 1421 - 1425. [Full Text] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673